Strategy Asset Managers’s Roivant Sciences ROIV Stock Holding History

Strategy Asset Managers’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Buy	+5,872	New	+$174K	0.03%	261

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Strategy Asset Managers's ROIV Position: Q2 2026 in Review

Strategy Asset Managers opened a new position in Roivant Sciences (ROIV) in Q2 2026: 5,872 shares worth $208K. The stake represents 0.03% of the portfolio and ranks #261 among its holdings.

498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Strategy Asset Managers held 5,872 shares of Roivant Sciences worth $208K as of Q2 2026.
Roivant Sciences was a new Strategy Asset Managers position in Q2 2026.
Roivant Sciences made up 0.03% of Strategy Asset Managers's portfolio in Q2 2026, its #261 holding.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Strategy Asset Managers's 13F filing for Q2 2026, filed 14 Aug 2026.